AbCellera Biologics Inc. (ABCL)
AbCellera Biologics Inc. (ABCL) from its SEC filings: 2025 revenue $75.1 million (+161% vs the year before), net margin -195%, free cash flow -$174.1 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $75.1 million |
| Revenue growth | +161% |
| Net income | -$146.4 million |
| Net margin | -194.9% |
| Free cash flow | -$174.1 million |
| Diluted EPS | $-0.49 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | -76% |
| Cash | $120.1 million |
| Share count, 1 year | +3% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.